Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy.

Shropshire EL, Chaudhry M, Miller CM, Allen BC, Bozdogan E, Cardona DM, King LY, Janas GL, Do RK, Kim CY, Ronald J, Bashir MR.

Radiology. 2019 Apr 30:182135. doi: 10.1148/radiol.2019182135. [Epub ahead of print]

PMID:
31038409
2.

An update for LI-RADS: Version 2018. Why so soon after version 2017?

Kielar AZ, Chernyak V, Bashir MR, Do RK, Fowler KJ, Santillan C, Sirlin CB, Mitchell DG, Cerny M, Tang A, Elsayes KM, Kamaya A, Kono Y, Arora SS.

J Magn Reson Imaging. 2019 Mar 12. doi: 10.1002/jmri.26715. [Epub ahead of print] No abstract available.

PMID:
30864185
3.

LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance.

Elsayes KM, Kielar AZ, Chernyak V, Morshid A, Furlan A, Masch WR, Marks RM, Kamaya A, Do RKG, Kono Y, Fowler KJ, Tang A, Bashir MR, Hecht EM, Jambhekar K, Lyshchik A, Rodgers SK, Heiken JP, Kohli M, Fetzer DT, Wilson SR, Kassam Z, Mendiratta-Lala M, Singal AG, Lim CS, Cruite I, Lee J, Ash R, Mitchell DG, McInnes MDF, Sirlin CB.

J Hepatocell Carcinoma. 2019 Feb 5;6:49-69. doi: 10.2147/JHC.S186239. eCollection 2019. Review.

4.

Pilot study of rapid MR pancreas screening for patients with BRCA mutation.

Corrias G, Raeside MC, Agostini A, Huicochea-Castellanos S, Aramburu-Nunez D, Paudyal R, Shukla-Dave A, Smelianskaia O, Capanu M, Zheng J, Fung M, Kelsen DP, Mangino DA, Robson ME, Goldfrank DJ, Carter J, Allen PJ, Conti B, Monti S, Do RKG, Mannelli L.

Eur Radiol. 2019 Jan 28. doi: 10.1007/s00330-018-5975-0. [Epub ahead of print]

PMID:
30689033
5.

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.

Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika I, Do RK, Sun Y, Kingham TP, D'Angelica MI, Berger MF, Hyman DM, Jarnagin W, Klimstra DS, Janjigian YY, Solit DB, Schultz N, Abou-Alfa GK.

Clin Cancer Res. 2019 Apr 1;25(7):2116-2126. doi: 10.1158/1078-0432.CCR-18-2293. Epub 2018 Oct 29.

PMID:
30373752
6.

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.

Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M, Roshal M, Do RK, Zehir A, You D, Selcuklu SD, Viale A, Tallman MS, Hyman DM, Reznik E, Finley LWS, Papaemmanuil E, Tosolini A, Frattini MG, MacBeth KJ, Liu G, Fan B, Choe S, Wu B, Janjigian YY, Mellinghoff IK, Diaz LA, Levine RL, Abou-Alfa GK, Stein EM, Intlekofer AM.

Cancer Discov. 2018 Dec;8(12):1540-1547. doi: 10.1158/2159-8290.CD-18-0877. Epub 2018 Oct 24.

PMID:
30355724
7.

Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients.

Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, Kono Y, Do RK, Mitchell DG, Singal AG, Tang A, Sirlin CB.

Radiology. 2018 Dec;289(3):816-830. doi: 10.1148/radiol.2018181494. Epub 2018 Sep 25.

PMID:
30251931
8.

CT radiomics to predict high-risk intraductal papillary mucinous neoplasms of the pancreas.

Chakraborty J, Midya A, Gazit L, Attiyeh M, Langdon-Embry L, Allen PJ, Do RKG, Simpson AL.

Med Phys. 2018 Nov;45(11):5019-5029. doi: 10.1002/mp.13159. Epub 2018 Sep 27.

PMID:
30176047
9.

White paper of the Society of Abdominal Radiology hepatocellular carcinoma diagnosis disease-focused panel on LI-RADS v2018 for CT and MRI.

Elsayes KM, Kielar AZ, Elmohr MM, Chernyak V, Masch WR, Furlan A, Marks RM, Cruite I, Fowler KJ, Tang A, Bashir MR, Hecht EM, Kamaya A, Jambhekar K, Kamath A, Arora S, Bijan B, Ash R, Kassam Z, Chaudhry H, McGahan JP, Yacoub JH, McInnes M, Fung AW, Shanbhogue K, Lee J, Deshmukh S, Horvat N, Mitchell DG, Do RKG, Surabhi VR, Szklaruk J, Sirlin CB.

Abdom Radiol (NY). 2018 Oct;43(10):2625-2642. doi: 10.1007/s00261-018-1744-4.

PMID:
30155697
10.

Comparison of Navigator Triggering Reduced Field of View and Large Field of View Diffusion-Weighted Imaging of the Pancreas.

Mannelli L, Monti S, Corrias G, Fung MM, Nyman C, Golia Pernicka JS, Do RKG.

J Comput Assist Tomogr. 2019 Jan/Feb;43(1):143-148. doi: 10.1097/RCT.0000000000000778.

PMID:
30119065
11.

Preoperative risk prediction for intraductal papillary mucinous neoplasms by quantitative CT image analysis.

Attiyeh MA, Chakraborty J, Gazit L, Langdon-Embry L, Gonen M, Balachandran VP, D'Angelica MI, DeMatteo RP, Jarnagin WR, Kingham TP, Allen PJ, Do RK, Simpson AL.

HPB (Oxford). 2019 Feb;21(2):212-218. doi: 10.1016/j.hpb.2018.07.016. Epub 2018 Aug 7.

PMID:
30097414
12.

Intrahepatic Cholangiocarcinomas Have Histologically and Immunophenotypically Distinct Small and Large Duct Patterns.

Sigel CS, Drill E, Zhou Y, Basturk O, Askan G, Pak LM, Vakiani E, Wang T, Boerner T, Do RKG, Simpson AL, Jarnagin W, Klimstra DS.

Am J Surg Pathol. 2018 Oct;42(10):1334-1345. doi: 10.1097/PAS.0000000000001118.

PMID:
30001234
13.

A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.

Harding JJ, Do RK, Dika IE, Hollywood E, Uhlitskykh K, Valentino E, Wan P, Hamilton C, Feng X, Johnston A, Bomalaski J, Li CF, O'Reilly EM, Abou-Alfa GK.

Cancer Chemother Pharmacol. 2018 Sep;82(3):429-440. doi: 10.1007/s00280-018-3635-3. Epub 2018 Jul 3.

PMID:
29971467
14.

Convolutional neural networks: an overview and application in radiology.

Yamashita R, Nishio M, Do RKG, Togashi K.

Insights Imaging. 2018 Aug;9(4):611-629. doi: 10.1007/s13244-018-0639-9. Epub 2018 Jun 22. Review.

15.

Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases.

Creasy JM, Midya A, Chakraborty J, Adams LB, Gomes C, Gonen M, Seastedt KP, Sutton EJ, Cercek A, Kemeny NE, Shia J, Balachandran VP, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D'Angelica MI, Do RKG, Simpson AL.

Eur Radiol. 2019 Jan;29(1):458-467. doi: 10.1007/s00330-018-5542-8. Epub 2018 Jun 19.

PMID:
29922934
16.

Short-term reproducibility of radiomic features in liver parenchyma and liver malignancies on contrast-enhanced CT imaging.

Perrin T, Midya A, Yamashita R, Chakraborty J, Saidon T, Jarnagin WR, Gonen M, Simpson AL, Do RKG.

Abdom Radiol (NY). 2018 Dec;43(12):3271-3278. doi: 10.1007/s00261-018-1600-6.

PMID:
29730738
17.

Rapid switching kVp dual energy CT: Value of reconstructed dual energy CT images and organ dose assessment in multiphasic liver CT exams.

Mahmood U, Horvat N, Horvat JV, Ryan D, Gao Y, Carollo G, DeOcampo R, Do RK, Katz S, Gerst S, Schmidtlein CR, Dauer L, Erdi Y, Mannelli L.

Eur J Radiol. 2018 May;102:102-108. doi: 10.1016/j.ejrad.2018.02.022. Epub 2018 Feb 19.

18.

LI-RADS 2017: An update.

Kielar AZ, Chernyak V, Bashir MR, Do RK, Fowler KJ, Mitchell DG, Cerny M, Elsayes KM, Santillan C, Kamaya A, Kono Y, Sirlin CB, Tang A.

J Magn Reson Imaging. 2018 Jun;47(6):1459-1474. doi: 10.1002/jmri.26027. Epub 2018 Apr 6. Review.

PMID:
29626376
19.

Intrahepatic cholangiocarcinoma: can imaging phenotypes predict survival and tumor genetics?

Aherne EA, Pak LM, Goldman DA, Gonen M, Jarnagin WR, Simpson AL, Do RK.

Abdom Radiol (NY). 2018 Oct;43(10):2665-2672. doi: 10.1007/s00261-018-1505-4.

PMID:
29492607
20.

Influence of CT acquisition and reconstruction parameters on radiomic feature reproducibility.

Midya A, Chakraborty J, Gönen M, Do RKG, Simpson AL.

J Med Imaging (Bellingham). 2018 Jan;5(1):011020. doi: 10.1117/1.JMI.5.1.011020. Epub 2018 Feb 15.

21.

Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma.

Mier-Hicks A, Raj M, Do RK, Yu KH, Lowery MA, Varghese A, O'Reilly EM.

Clin Colorectal Cancer. 2018 Jun;17(2):121-128. doi: 10.1016/j.clcc.2018.01.008. Epub 2018 Jan 31.

PMID:
29477452
22.

Quantitative Imaging Features and Postoperative Hepatic Insufficiency: A Multi-Institutional Expanded Cohort.

Pak LM, Chakraborty J, Gonen M, Chapman WC, Do RKG, Groot Koerkamp B, Verhoef K, Lee SY, Massani M, van der Stok EP, Simpson AL; Memorial Sloan Kettering Cancer Center Hepatopancreatobiliary Service.

J Am Coll Surg. 2018 May;226(5):835-843. doi: 10.1016/j.jamcollsurg.2018.02.001. Epub 2018 Feb 15.

23.

Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis.

Attiyeh MA, Chakraborty J, Doussot A, Langdon-Embry L, Mainarich S, Gönen M, Balachandran VP, D'Angelica MI, DeMatteo RP, Jarnagin WR, Kingham TP, Allen PJ, Simpson AL, Do RK.

Ann Surg Oncol. 2018 Apr;25(4):1034-1042. doi: 10.1245/s10434-017-6323-3. Epub 2018 Jan 29.

PMID:
29380093
24.

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.

O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP.

Cancer. 2018 Apr 1;124(7):1374-1382. doi: 10.1002/cncr.31218. Epub 2018 Jan 16.

25.

Imaging for pancreatic ductal adenocarcinoma.

Horvat N, Ryan DE, LaGratta MD, Shah PM, Do RK.

Chin Clin Oncol. 2017 Dec;6(6):62. doi: 10.21037/cco.2017.11.03.

26.

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.

Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM.

Eur J Cancer. 2018 Jan;89:19-26. doi: 10.1016/j.ejca.2017.11.004. Epub 2017 Dec 8.

PMID:
29223478
27.

Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma?

Pak LM, Gonen M, Seier K, Balachandran VP, D'Angelica MI, Jarnagin WR, Kingham TP, Allen PJ, Do RKG, Simpson AL.

Abdom Radiol (NY). 2018 Aug;43(8):2113-2118. doi: 10.1007/s00261-017-1407-x.

PMID:
29177926
28.

Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Tang A, Bashir MR, Corwin MT, Cruite I, Dietrich CF, Do RKG, Ehman EC, Fowler KJ, Hussain HK, Jha RC, Karam AR, Mamidipalli A, Marks RM, Mitchell DG, Morgan TA, Ohliger MA, Shah A, Vu KN, Sirlin CB; LI-RADS Evidence Working Group.

Radiology. 2018 Jan;286(1):29-48. doi: 10.1148/radiol.2017170554. Epub 2017 Nov 21. Review.

PMID:
29166245
29.

2017 Version of LI-RADS for CT and MR Imaging: An Update.

Elsayes KM, Hooker JC, Agrons MM, Kielar AZ, Tang A, Fowler KJ, Chernyak V, Bashir MR, Kono Y, Do RK, Mitchell DG, Kamaya A, Hecht EM, Sirlin CB.

Radiographics. 2017 Nov-Dec;37(7):1994-2017. doi: 10.1148/rg.2017170098. Review.

PMID:
29131761
30.

Background, current role, and potential applications of radiogenomics.

Pinker K, Shitano F, Sala E, Do RK, Young RJ, Wibmer AG, Hricak H, Sutton EJ, Morris EA.

J Magn Reson Imaging. 2018 Mar;47(3):604-620. doi: 10.1002/jmri.25870. Epub 2017 Nov 2. Review.

31.

Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma Using Quantitative Image Analysis.

Zheng J, Chakraborty J, Chapman WC, Gerst S, Gonen M, Pak LM, Jarnagin WR, DeMatteo RP, Do RKG, Simpson AL; Hepatopancreatobiliary Service in the Department of Surgery of the Memorial Sloan Kettering Cancer Center; Research Staff in the Department of Surgery at Washington University School of Medicine.

J Am Coll Surg. 2017 Dec;225(6):778-788.e1. doi: 10.1016/j.jamcollsurg.2017.09.003. Epub 2017 Sep 21.

32.

Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.

Kielar A, Fowler KJ, Lewis S, Yaghmai V, Miller FH, Yarmohammadi H, Kim C, Chernyak V, Yokoo T, Meyer J, Newton I, Do RK.

Abdom Radiol (NY). 2018 Jan;43(1):218-230. doi: 10.1007/s00261-017-1281-6. Review.

33.

Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014.

Horvat N, Nikolovski I, Long N, Gerst S, Zheng J, Pak LM, Simpson A, Zheng J, Capanu M, Jarnagin WR, Mannelli L, Do RKG.

Abdom Radiol (NY). 2018 Jan;43(1):169-178. doi: 10.1007/s00261-017-1261-x.

PMID:
28765978
34.

An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses.

Vasan N, Braghiroli MI, Shoushtari AN, Do RKG, Edelweiss M, Shamseddine A, Faraj W, Mukherji D, Haydar A, Olayan A, Sabatin F, Assi R, El Dika I, Saltz LB, Abou-Alfa GK, O'Reilly EM.

J Gastrointest Oncol. 2017 Jun;8(3):596-602. doi: 10.21037/jgo.2017.01.21. No abstract available.

35.

O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.

Raj N, Klimstra DS, Horvat N, Zhang L, Chou JF, Capanu M, Basturk O, Do RKG, Allen PJ, Reidy-Lagunes D.

Pancreas. 2017 Jul;46(6):758-763. doi: 10.1097/MPA.0000000000000842.

36.

Computed Tomography Image Texture: A Noninvasive Prognostic Marker of Hepatic Recurrence After Hepatectomy for Metastatic Colorectal Cancer.

Simpson AL, Doussot A, Creasy JM, Adams LB, Allen PJ, DeMatteo RP, Gönen M, Kemeny NE, Kingham TP, Shia J, Jarnagin WR, Do RKG, D'Angelica MI.

Ann Surg Oncol. 2017 Sep;24(9):2482-2490. doi: 10.1245/s10434-017-5896-1. Epub 2017 May 30.

37.

Liver Imaging Reporting and Data System: an expert consensus statement.

Elsayes KM, Kielar AZ, Agrons MM, Szklaruk J, Tang A, Bashir MR, Mitchell DG, Do RK, Fowler KJ, Chernyak V, Sirlin CB.

J Hepatocell Carcinoma. 2017 Feb 17;4:29-39. doi: 10.2147/JHC.S125396. eCollection 2017.

38.

Magnetic Resonanance Imaging of the Liver (Including Biliary Contrast Agents)-Part 2: Protocols for Liver Magnetic Resonanance Imaging and Characterization of Common Focal Liver Lesions.

Agostini A, Kircher MF, Do RK, Borgheresi A, Monti S, Giovagnoni A, Mannelli L.

Semin Roentgenol. 2016 Oct;51(4):317-333. doi: 10.1053/j.ro.2016.05.016. Epub 2016 May 30. Review. No abstract available.

39.

Imaging comparison of tubular and colloid pancreatic adenocarcinoma arising from intraductal papillary mucinous neoplasm on multidetector CT.

Escalon JG, Gerst S, Porembka M, Allen PJ, Do RK.

Clin Imaging. 2016 Nov - Dec;40(6):1195-1199. doi: 10.1016/j.clinimag.2016.08.011. Epub 2016 Aug 16.

40.

Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres.

Shady W, Sotirchos VS, Do RK, Pandit-Taskar N, Carrasquillo JA, Gonen M, Sofocleous CT.

AJR Am J Roentgenol. 2016 Sep;207(3):661-70. doi: 10.2214/AJR.15.15202. Epub 2016 Jul 6.

41.

Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.

Shady W, Kishore S, Gavane S, Do RK, Osborne JR, Ulaner GA, Gonen M, Ziv E, Boas FE, Sofocleous CT.

Eur J Radiol. 2016 Jun;85(6):1224-31. doi: 10.1016/j.ejrad.2016.03.029. Epub 2016 Mar 31.

42.

Colorectal Cancer Liver Metastases: Biopsy of the Ablation Zone and Margins Can Be Used to Predict Oncologic Outcome.

Sotirchos VS, Petrovic LM, Gönen M, Klimstra DS, Do RK, Petre EN, Garcia AR, Barlas A, Erinjeri JP, Brown KT, Covey AM, Alago W, Brody LA, DeMatteo RP, Kemeny NE, Solomon SB, Manova-Todorova KO, Sofocleous CT.

Radiology. 2016 Sep;280(3):949-59. doi: 10.1148/radiol.2016151005. Epub 2016 Mar 24.

43.

Intravoxel Incoherent Motion-derived Histogram Metrics for Assessment of Response after Combined Chemotherapy and Radiation Therapy in Rectal Cancer: Initial Experience and Comparison between Single-Section and Volumetric Analyses.

Nougaret S, Vargas HA, Lakhman Y, Sudre R, Do RK, Bibeau F, Azria D, Assenat E, Molinari N, Pierredon MA, Rouanet P, Guiu B.

Radiology. 2016 Aug;280(2):446-54. doi: 10.1148/radiol.2016150702. Epub 2016 Feb 26.

44.

Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone.

Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D'Angelica MI, Allen PJ, Erinjeri JP, Brody LA, O'Neill GP, Johnson KN, Garcia AR, Beattie C, Zhao B, Solomon SB, Schwartz LH, DeMatteo R, Abou-Alfa GK.

J Clin Oncol. 2016 Jun 10;34(17):2046-53. doi: 10.1200/JCO.2015.64.0821. Epub 2016 Feb 1.

45.

Inter-observer agreement on the assessment of relative liver lesion signal intensity on hepatobiliary phase imaging with gadoxetate (Gd-EOB-DTPA).

Ngu S, Lebron-Zapata L, Pomeranz C, Katz S, Gerst S, Zheng J, Moskowitz C, Do RK.

Abdom Radiol (NY). 2016 Jan;41(1):50-5. doi: 10.1007/s00261-015-0609-3.

46.

Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.

Konstantinidis IT, Groot Koerkamp B, Do RK, Gönen M, Fong Y, Allen PJ, D'Angelica MI, Kingham TP, DeMatteo RP, Klimstra DS, Kemeny NE, Jarnagin WR.

Cancer. 2016 Mar 1;122(5):758-65. doi: 10.1002/cncr.29824. Epub 2015 Dec 22.

47.

Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study.

Sadot E, Reidy-Lagunes DL, Tang LH, Do RK, Gonen M, D'Angelica MI, DeMatteo RP, Kingham TP, Groot Koerkamp B, Untch BR, Brennan MF, Jarnagin WR, Allen PJ.

Ann Surg Oncol. 2016 Apr;23(4):1361-70. doi: 10.1245/s10434-015-4986-1. Epub 2015 Nov 23.

48.

Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes.

Sofocleous CT, Violari EG, Sotirchos VS, Shady W, Gonen M, Pandit-Taskar N, Petre EN, Brody LA, Alago W, Do RK, D'Angelica MI, Osborne JR, Segal NH, Carrasquillo JA, Kemeny NE.

Clin Colorectal Cancer. 2015 Dec;14(4):296-305. doi: 10.1016/j.clcc.2015.06.003. Epub 2015 Jun 27.

49.

Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes.

Sadot E, Simpson AL, Do RK, Gonen M, Shia J, Allen PJ, D'Angelica MI, DeMatteo RP, Kingham TP, Jarnagin WR.

PLoS One. 2015 Jul 24;10(7):e0132953. doi: 10.1371/journal.pone.0132953. eCollection 2015.

50.

FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma.

Sadot E, Doussot A, O'Reilly EM, Lowery MA, Goodman KA, Do RK, Tang LH, Gönen M, D'Angelica MI, DeMatteo RP, Kingham TP, Jarnagin WR, Allen PJ.

Ann Surg Oncol. 2015 Oct;22(11):3512-21. doi: 10.1245/s10434-015-4647-4. Epub 2015 Jun 12.

Supplemental Content

Support Center